This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ionis (IONS) Q4 Earnings Decline Y/Y, Sales Beat Estimates
by Zacks Equity Research
Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.
Corcept (CORT) Q4 Earnings In Line, Revenues Miss Estimates
by Zacks Equity Research
Corcept's (CORT) earnings meet estimates in the fourth quarter of 2020 while revenues miss the same.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Johnson & Johnson
Viatris (VTRS) Declines on Lackluster Outlook, Announces Dividend
by Zacks Equity Research
Viatris (VTRS) declines after it announces outlook for 2021 and reaffirms strategic commitments.
What's in the Cards for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) fourth-quarter earnings call, investors are likely to focus on sales number for its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.
FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs
by Kinjel Shah
The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.
Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q4 Earnings
by Zacks Equity Research
Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2021 on the fourth-quarter earrings call.
Pfizer (PFE), BioNTech Test COVID-19 Vaccine in Pregnant Women
by Zacks Equity Research
Pfizer (PFE) and BioNTech begin dosing in a mid-to-late-stage study on their COVID-19 vaccine in healthy pregnant women.
Pharma Stock Roundup: Coronavirus Vaccine Updates From PFE, AZN & JNJ
by Kinjel Shah
WHO authorizes emergency use of AstraZeneca's (AZN) COVID-19 vaccine. J&J (JNJ) seeks conditional approval for its COVID-19 vaccine in EU.
Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to EU
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) win a deal for 200 million more doses of its COVID-19 vaccine in Europe.
J&J (JNJ) Seeks Conditional Nod for COVID-19 Vaccine in EU
by Zacks Equity Research
J&J's (JNJ) COVID-19 vaccine, if approved, will be the only COVID-19 vaccine to be approved for single administration.
Pfizer (PFE) Gets FDA Nod for New Indication of Immunoglobulin
by Zacks Equity Research
Pfizer's (PFE) Panzyga gets FDA approval to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disease.
AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod
by Zacks Equity Research
AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients.
AstraZeneca (AZN) Q4 Earnings, Sales Top Despite COVID-19 Woes
by Zacks Equity Research
AstraZeneca (AZN) surpasses fourth-quarter estimates on both counts. Stock up in pre-market.
Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Deciphera Pharmaceuticals (DCPH) reports narrower-than-expected loss. Nonetheless, sales marginally surpass estimates for the fourth quarter of 2020.
Bristol Myers (BMY) Gets European Commission Nod for Inrebic
by Zacks Equity Research
The European Commission approves Bristol Myers' (BMY) Inrebic for the treatment of adult patients with newly diagnosed and previously treated myelofibrosis.
Novartis (NVS) Gets Breakthrough Therapy Tag for Leukemia Drug
by Zacks Equity Research
Novartis' (NVS) asciminib gets Breakthrough Therapy tag by the FDA for the treatment of adult patients with Ph+ CML in chronic phase, previously treated with two or more tyrosine kinase inhibitors.
Glaxo's (GSK) Rukobia Gets EU Nod for Multidrug-Resistant HIV
by Zacks Equity Research
The approval of Glaxo's (GSK) Rukobia is based on data from the pivotal phase III BRIGHTE study. Rukobia was approved in the United States in July last year.
Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View
by Zacks Equity Research
Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021. Shares down in after-hours trading.
Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans
by Zacks Equity Research
Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.
The Zacks Analyst Blog Highlights: Google, Pfizer, Uber, Cisco Systems and ConocoPhillips
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Google, Pfizer, Uber, Cisco Systems and ConocoPhillips
Pharma ETFs in Focus Post Q4 Earnings
by Sweta Killa
Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.
Top Stock Reports for Alphabet, Pfizer & Uber
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Pfizer (PFE), and Uber Technologies (UBER).
J&J (JNJ) Seeks Emergency Approval for Coronavirus Vaccine
by Zacks Equity Research
Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking emergency use approval for its single-shot coronavirus vaccine.
Pharma Stock Roundup: PFE, MRK Q4 Earnings, AZN, JNJ Coronavirus Vaccine Updates
by Kinjel Shah
Several companies announce Q4 results. J&J (JNJ) and AstraZeneca (AZN) provide updates on their respective COVID-19 vaccines.